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ORIGINAL ARTICLE
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diagnosed multiple myeloma: results from a systematic literature review
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aNational Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust,
Oxford, UK; bCelgene International, Boudry, Switzerland; cBristol Medical School, University of Bristol, Bristol, UK; dCogentia
Healthcare Consulting Ltd, Cambridge, UK; eDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section of
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ABSTRACT
Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple
myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib
(VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treat-
ments for TNE NDMM include Rd plus bortezomib (RVd) and daratumumab plus VMP (VMPþD),
daratumumab plus lenalidomide and dexamethasone (Dþ Rd). Relative efficacy of these treat-
ments was compared using a network meta-analysis. Eight trials identified by a systematic litera-
ture review were included in the primary analysis; hazard ratios (HRs) for overall survival (OS)
and progression-free survival (PFS) were used. Rd was superior to other MP-based regimens for
OS and PFS. There was strong evidence that, compared with Rd, both Dþ Rd and RVd improved
PFS (HR 0.57; 95% credible interval (CrI) 0.43, 0.73 and HR 0.72; 95% CrI 0.56, 0.91, respectively).
However, there was strong evidence only for RVd in respect to OS (HR 0.72; 95% CrI 0.52, 0.96).
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Multiple myeloma (MM) accounts for approximately
10% of hematologic cancers and is more commonly
diagnosed in older patients (median age at diagnosis
72 years in European patients) [1].
Induction therapy followed by high-dose chemo-
therapy with autologous stem cell transplantation
(ASCT) is the standard treatment for patients with
newly diagnosed MM (NDMM) who are aged
<65 years or fit and aged 70 years [1]. For patients
aged >70 years and those unfit for ASCT, several
chemotherapy regimens are recommended [1,2]. The
2017 European Society for Medical Oncology (ESMO)
guidelines include bortezomib, melphalan, and pred-
nisone (VMP), lenalidomide plus dexamethasone (Rd),
or lenalidomide, bortezomib, and dexamethasone
(RVd) as preferred first-line options, and several alter-
native triplets, including melphalan, prednisone, and
thalidomide (MPT), and bortezomib, cyclophospha-
mide, and dexamethasone (VCD) [1].
The National Comprehensive Cancer NetworkVR
(NCCNVR ) Clinical Practice Guidelines in Oncology
(NCCN GuidelinesVR ) include RVd, Rd, VCD, and daratu-
mumab plus Rd (Dþ Rd) as preferred treatment
options for NDMM patients not intended for ASCT
(TNE); furthermore, NCCN GuidelinesVR state that older
melphalan-containing regimens are no longer to be
considered standard of care (SoC) in the United States
because novel agents are available and accessible [2].
Despite the growing treatment options for TNE
patients with NDMM, very few regimens have been
directly compared. Therefore, network meta-analysis
(NMA), a statistical method used to simultaneously
evaluate the comparative efficacy of several treatment
options by direct and indirect comparisons, is a useful
tool [3].
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A previous NMA [4] evaluated the relative efficacy
of Rd versus VMP, melphalan and prednisone (MP),
and MPT for TNE NDMM patients. In this analysis,
involving five trials published between 1988 and 2015,
the authors reported statistically significant differences
(p< 0.05) in overall survival (OS) and progression-free
survival (PFS) in favor of Rd versus MP, MPT, and VMP.
Although newer treatment combination regimens
are becoming available, their role in the management
of NDMM remains undefined. We report the results of
the NMA that includes the newer regimens Dþ Rd,
RVd, and daratumumab plus VMP (VMPþD), in add-
ition to established options Rd, MP, MPT, and VMP.
Methods
Systematic literature review
The systematic literature review (SLR) methodology
was based on Weisel et al. [4]. Articles from January 1,
1988 to July 2, 2019 were reviewed to identify rele-
vant randomized controlled trials (RCT) evaluating effi-
cacy in TNE patients with NDMM. The original
searches were carried out in March 2016. Subsequent
updates were carried out in November 2016, August
2017, January 2018, and July 2019.
Eligibility criteria
Articles were selected using the Population,
Intervention, Comparators, Outcomes, and Study
design criteria [5]. The population was limited to
patients with NDMM or untreated MM who were aged
65 years or aged <65 years and TNE. Studies with
<10 patients per arm were excluded. The interven-
tions of interest included lenalidomide, thalidomide,
or bortezomib (as monotherapy or part of a combin-
ation treatment), older MP-based combination regi-
mens, and newer regimens including Dþ Rd, RVd,
VMPþD, and carfilzomib in combination with melpha-
lan and prednisone (KMP). Comparators of interest
were placebo, any of the previously mentioned inter-
ventions at a different dose or treatment duration, or
any other active antimyeloma drug as monotherapy
or as part of combination treatment. Endpoints of
interest were OS, PFS, and response rate. Only pub-
lished RCTs and conference abstracts were eligible
for inclusion.
Search strategies
Embase, MEDLINE, and the Cochrane Central Register
of Controlled Trials were searched for relevant articles
published in the English language. Conference
proceedings from ESMO, American Society of Clinical
Oncology, American Society of Hematology, European
Hematology Association, International Myeloma
Workshop, and the International Society for
Pharmacoeconomics and Outcomes Research were
manually searched. The US National Institutes of
Health Clinical Trial Registry was also searched for
completed, unpublished trials with available results.
Bibliographies of articles identified in the searches
were manually checked.
The searches were conducted in four phases: an ori-
ginal search (carried out on March 14, 2016) and four
updates (carried out on November 8, 2016, August 8,
2017, January 8, 2018, and July 2, 2019). The search
strategy is provided in Supplementary Appendix 1.
Study selection
All abstracts identified were independently screened
by two investigators. Eligible abstracts received full-
text screening and review, which was carried out by
the same two investigators. Discrepancies between
the investigators were resolved through discussion
with a third investigator. Articles meeting eligibility cri-
teria at full-text screening were included. If there were
multiple articles on a single trial population, only the
most recent or most relevant data were included in
the analysis.
Data collection and data items
Study characteristics, patient characteristics, treatment,
and efficacy outcomes were extracted from all
included articles.
Hazard ratios (HRs) were extracted for OS and PFS
endpoints. If Kaplan–Meier curves were presented,
they were digitized and used to estimate HRs [6]. If
these were unavailable, they were estimated as
described by Tierney et al [7]. If HRs were available
but confidence intervals (CIs) were not, then these
were estimated using p values and their correspond-
ing z-scores used to calculate the standard error. If
only number, probability, or percentages of patients
alive were reported, then HR and CIs were estimated
using formulae based on the log-rank test.
Risk of bias
The quality of individual publications was assessed by
two independent investigators using the Cochrane
Collaboration’s tool for assessing the risk of bias in
randomized trials [8]. Any differences were resolved
through discussion with a third reviewer.
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NMA
To determine the comparative efficacy of treatments,
a Bayesian NMA was conducted on the HRs for OS
and PFS using both fixed- and random-effects models.
Model fit was assessed using the deviance information
criterion (DIC). Parameters for the model were esti-
mated using a Markov Chain Monte Carlo method in
the OpenBUGS software package version 3.2.3
(OpenBUGS Project Management Group, Cambridge,
UK; http://www.openbugs.net). The model used nor-
mal, noninformative prior distributions for the parame-
ters to be investigated (mean ¼ 0, variance ¼ 10,000).
Model fit was assessed by comparison of total residual
deviance to the number of data points in the network;
an overall assessment of complexity and fit was pro-
vided by the DIC.
Reported log HRs and their associated standard
errors were synthesized. When trials have more than
two arms, there is an induced correlation in the HRs
because the same control arm is used more than
once. For multi-arm trials, a multivariate normal likeli-
hood with covariance equal to the log HR of the con-
trol arm was used [9]. If the variance for the control
arm was not reported, then it was estimated as the
average of the reported variances of the log
HRs [10,11].
Primary and extended evidence networks were
plotted for OS and PFS, where nodes represent treat-
ments and lines connecting treatment nodes represent
trials comparing those treatments. Node size is pro-
portional to the number of trials that evaluated the
treatment; line thickness is proportional to the number
of trials comparing the treatments [12,13].
Inconsistency was assessed using an independent
means model that does not make assumptions about
consistency of treatment effects. Inconsistency was
indicated if the residual deviance and DIC of this
model were substantially lower than for the base-case
model [14].
Analyses were carried out on an intention-to-treat
(ITT) basis using Rd as the reference treatment. Results
are presented as mean HRs for OS and PFS with their
credible intervals (CrIs), where an HR <1 indicates a
beneficial effect.
The overall ranking of each treatment in terms of
OS and PFS was generated by plotting surface under
the cumulative ranking (SUCRA) curves.
Sensitivity analyses
A sensitivity analysis was carried out on HRs for OS
and PFS in the extended evidence network, focusing
on RVd, Dþ Rd, Rd, MPT, MP, VMP, and VMPþD. To
explore the effect of the difference in age between
treatment groups in the SWOG S0777 trial (RVd vs Rd)
[15], a sensitivity analysis was carried out on age-
adjusted HRs from this study in both the primary
and extended networks. A fixed-effect model was
used for sensitivity analyses of the primary network,




The SLR yielded 9,176 abstracts. After initial screening,
282 abstracts underwent full-text review. Of these, 238
were excluded; the most common reasons for exclu-
sion were incorrect study population (n¼ 79) and
inappropriate study design (n¼ 57). The analysis
included 44 publications describing 26 RCTs (Figure 1).
Risk of bias
Trials in the primary network generally had a low-risk
of bias regarding blinding of outcome assessment and
incomplete outcome data (Supplementary Appendix
2). In IFM 99-06, there appeared to be imbalance in
the proportion of patients with chromosomal translo-
cations in the MP versus MPT arms, and more patients
in the MP arm received second-line therapies versus
the MPT arm. In the SWOG S0777 trial the Rd arm
contained a higher proportion of patients aged
65 years (48%) than the RVd arm (38%), and 10% of
patients in the trial received ASCT (the proportion in
each arm was not reported).
Evidence networks
A conservative approach was used to construct the
primary analysis network, excluding trials based on
lack of relevance to clinical practice and/or adherence
to the Summary of Product Characteristics. Overall,
eight trials (ALCYONE, MAIA, VISTA, IFM 01/01, IFM 99-
06, MM03, FIRST, and SWOG S0777) which evaluated
seven treatment regimens: Dþ Rd, MP, MPT, Rd, RVd,
VMP, and VMPþD were included in the primary ana-
lysis [11,16–25] (Table 1).
The primary analysis network had a simple geom-
etry with a single evidence path between all treat-
ment nodes and no clustering of nodes. As the OS
data from the ALCYONE [24] and MAIA [25] trials were
immature, only the PFS network included the Dþ Rd
and VMPþD treatment nodes. In both the OS and
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PFS networks, three trials contributed to the MP ver-
sus MPT comparison; all other comparisons involved
one trial each. Rd was directly compared with both
Dþ Rd, RVd and MPT, but it was separated from other
treatment options by two to four indirect steps
(Figure 2).
The extended networks had a more complicated
geometry but only made small modifications to the
evidence contributing to our key comparisons (Dþ Rd,
RVd, Rd, MPT, MP, VMP, and VMPþD; Figure 2). The
main difference was greater heterogeneity of the
included studies, favoring the random-effects analyses
chosen for sensitivity analyses of the overall networks.
Assessment of inconsistency
There were no closed loops of evidence in the primary
analysis networks, so inconsistency could not be
assessed. In the extended networks, the residual
deviance and DIC for the independent-means models
did not indicate that inconsistency was present in
either the OS or PFS networks [14], nor for either ITT
or age-adjusted results from SWOG S0777 [15]
(Supplementary Appendix 3).
Primary analysis
Baseline age was similar across the studies (Table 2), apart
from SWOG S0777 (median age 63 years vs >70 years for
the other trials). The proportion of patients with
International Staging Score (ISS) stage 3 disease was
slightly lower (30%) in the three trials evaluating MPT
[16,19–21] versus trials of bortezomib- and lenalidomide-
based regimens (29%–41%) [11,15,17,18,21–25].
The similarity of the trial designs and small number
of studies included in the primary network suggested
low heterogeneity. Thus, a fixed-effects model was
used. This was supported by the similarity of both the
DIC and residual deviance statistics across fixed- and
random-effects models (Supplementary Appendix 3).
Analysis of OS showed evidence of Rd superiority
over MP, MPT, and VMP (Figure 3(A)). RVd was the
only therapy with evidence of superiority over Rd (HR
0.72, 95% CrI 0.52, 0.96; Figure 3(A)). The impact on
OS for VMPþD versus Rd could not be assessed due
the absence of mature OS data for VMPþD.
Similarly, for PFS, there was evidence that Rd was
superior to MP, MPT, and VMP. Compared with Rd, there
was evidence that both Dþ Rd and RVd improved PFS
(HR 0.57; 95% CrI 0.43, 0.73 and HR 0.72; 95% CrI 0.56,
Figure 1. PRISMA flow diagram for SLR and NMA study selection. NMA: network meta-analysis; PRISMA: Preferred Reporting Items
for Systematic Reviews and Meta-Analyses; SLR: systematic literature review.
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0.91, respectively; Figure 3(B)). Results for VMPþD ver-
sus Rd were inconclusive for PFS.
Contingency tables for the primary analyses can be
found in Supplementary Appendix 4. SUCRA rankings
confirmed these findings (Figure 4).
Sensitivity analyses
In extending the network of trials, a random-effects
model for both PFS and OS was used, as suggested by
greater heterogeneity across trials and supported by
the lower DIC and deviance on the PFS outcome
(Supplementary Appendix 3). Rd maintained the PFS
improvement over MPT and VMP, as well as RVd over
Rd, but the inclusion of additional indirect evidence
resulted in broader CrIs. Analysis of the primary net-
work using age-adjusted HRs from the SWOG S0777
trial also provided evidence that Rd was superior to
MP, MPT, and VMP in terms of both PFS and OS
(Supplementary Appendix 5). Both Dþ Rd and RVd
improved PFS versus Rd (HR 0.57; 95% CrI 0.43, 0.73
and HR 0.73; 95% CrI 0.58, 0.92, respectively), and RVd
also marginally improved OS versus Rd (HR 0.75; 95%
CrI 0.55, 0.99). SUCRA rankings confirmed these find-
ings (Supplementary Appendix 6).
Sensitivity analyses incorporating evidence from the
extended network and random effects indicated none
of the treatments had strong evidence of superiority
to Rd in terms of PFS or OS in either the ITT analysis
(Supplementary Appendix 7) or the age-adjusted ana-
lysis (Supplementary Appendix 8). Point estimates
were similar to the results from the primary network,
but CrIs were wider, reflecting the adoption of random
effects.
Table 1. Extracted efficacy data from RCTs in the primary and extended analysis networks.
Study Comparison (N patients) PFS HR (95% CI) OS HR (95% CI)
Primary analysis network
FIRST [11] Rd (535) vs MPT (547) 0.69 (0.59–0.80) 0.78 (0.67–0.92)
IFM 01/01 [19] MPT (113) vs MP (116) 0.62 (0.47–0.82)a 0.68 (0.48–0.96)a
IFM 99-06 [16] MPT (125) vs MP (196) 0.51 (0.39–0.67) 0.59 (0.46–0.81)
MM03 [21] MPT (64) vs MP (54) 0.67 (0.38–1.18)b 0.42 (0.18–0.98)a
VISTA [22] VMP (344) vs MP (388) 0.56 (0.43–0.72) 0.69 (0.57–0.85)
SWOG S0777 [15] RVd (264) vs Rd (261) 0.71 (0.56–0.91) 0.71 (0.52–0.96)
ALCYONE [24] VMPþD (350) vs VMP (356) 0.50 (0.38–0.65) NR
MAIA [25] Dþ Rd (368) vs Rd (369) 0.56 (0.43–0.73) NR
Additional studies in extended analysis network
AFAC [26] TD (145) vs MP (143) 1.30 (0.95–1.78) 1.55 (1.06–2.27)
CLARION [27] KMP (478) vs VMP (477) 0.91 (0.75–1.10) 1.21 (0.90–1.64)
E1A06 [28] MPTþ T (154) vs MPRþ R (152) 0.84 (0.64–1.09) 0.88 (0.63–1.24)c
FIRST [11] Rd18 (541) vs MPT (547) 0.99 (0.86–1.14) 0.77 (0.66–0.90)
GEM05 [29,30] VMP (130) vs VTP (130) 1.20 (0.90–1.70) 0.67 (0.49–0.91)
GIMEMA [31] MPTþ T (167) vs MP (164) 0.63 (0.48–0.81) 1.04 (0.76–1.44)
GIMEMA-MM-03-05 [32] VMPTþ VT (254) vs VMP (257) 0.58 (0.47–0.71) 0.70 (0.52–0.92)
HOVON-49 [33] MPTþ T (165) vs MP (168) 0.54 (0.38–0.76)b 0.84 (0.61–1.16)b
HOVON-87/NMSG18 [34,35] MPRþ R (280) vs MPTþ T (280) 0.84 (0.70–1.05) 0.79 (0.60–1.05)
Hungria [36] CTD (32) vs MPT (32) 0.89 (0.48–1.64) 1.08 (0.54–2.19)
IFM-95/01 [37] MD (118) vs MP (122) 0.86 (0.65–1.13) 0.85 (0.62–1.17)b
D (127) vs MP (122) 1.70 (1.30–2.22)b 1.14 (0.84–1.55)b
D-IFN (121) vs MP (122) 1.46 (1.12–1.92)b 1.10 (0.80–1.50)b
Magarotto [38] Rd (217) vs CPRþMPR (437) 1.10 (0.90–1.35) 1.06 (0.78–1.43)
MM-015 [10] MPR (153) vs MPRþ R (152) 2.04 (1.43–2.94)a 1.27 (0.85–1.89)a
MP (154) vs MPRþ R (152) 2.50 (1.75–3.57)a 1.05 (0.69–1.60)
MRC Myeloma IX [39] CTDa (426) vs MP (423) 0.82 (0.70–0.96) 0.89 (0.74–1.08)
Myeloma XI [40] CTD (924) vs CRD (928) 0.96 (0.86–1.07) 0.92 (0.79–1.07)
NMSG [41] MPTþ T (182) vs MP (175) 0.89 (0.70–1.13) 1.12 (0.85–1.47)
San-Miguel [42] VMPþ S (52) vs VMP (54) 1.00 (0.58–1.75)b 1.00 (0.33–3.00)c
TMSG [43] MPTþ T (58) vs MP (57) 0.70 (0.42–1.17) 0.86 (0.46–1.60)a
UPFRONT [44] VMP (167) vs VD (168) 1.00 (0.78–1.29)b 0.96 (0.65–1.41)b
CI: confidence interval; CPRþMPR: cyclophosphamide, prednisone, and lenalidomide plus melphalan, prednisone, and lenalidomide; CRD: cyclophospha-
mide, lenalidomide, and dexamethasone; CTD: cyclophosphamide, thalidomide, and dexamethasone; CTDa: cyclophosphamide, thalidomide, and dexa-
methasone (attenuated); D: dexamethasone; D-IFN: dexamethasone and interferon alpha; Dþ Rd: daratumumab, lenalidomide, and dexamethasone; HR:
hazard ratio; KMP: carfilzomib, melphalan, and prednisone; MD: melphalan and dexamethasone; MP: melphalan and prednisone; MPR: melphalan, pred-
nisone, and lenalidomide; MPRþ R: melphalan, prednisone, and lenalidomide plus lenalidomide maintenance; MPT: melphalan, prednisone, and thalido-
mide; MPTþ T: melphalan, prednisone, and thalidomide plus thalidomide maintenance; NR: not reached; PFS: progression-free survival; OS: overall
survival; Rd: lenalidomide and dexamethasone; Rd18: lenalidomide in 3 of 4-week cycles; RCT: randomized controlled trial; RVd: lenalidomide, bortezomib,
and dexamethasone; TD: thalidomide and dexamethasone; VD: bortezomib and dexamethasone; VMP: bortezomib, melphalan, and prednisone; VMPþD:
bortezomib, melphalan, prednisone, and daratumumab; VMPþ S: bortezomib, melphalan, and prednisone plus siltuximab maintenance; VMPTþ VT: bor-
tezomib, melphalan, prednisone, and thalidomide plus thalidomide maintenance; VTP, bortezomib, thalidomide, and prednisone.
aCI estimated from p-value.
bHR and CI estimated from the Kaplan–Meier curve.
cHR and CI estimated from number of deaths and survival rate.
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Discussion
This NMA informs the relative effectiveness of estab-
lished and newer therapies for the management of
TNE NDMM versus current SoC. The results suggest
that Dþ Rd, Rd, RVd, and VMPþD provide clinically
relevant benefits over VMP, MPT, and MP, and that
Dþ Rd and RVd provide benefits over Rd.
Our analysis found evidence that Rd offers a PFS
advantage versus VMP. This agrees with several phase-
3 studies, which show a median PFS for Rd of
26.0–31.9months [15,18,25] versus 18.1–20.0 months
for VMP [22,24]. Compared with Rd alone, the Rd-
based combination regimens of RVd and Dþ Rd pro-
vided additional benefit in terms of PFS. Moreover,
Figure 2. Evidence networks. (A) Overall survival (OS). (B) Progression-free survival (PFS). CPR + MPR: cyclophosphamide, prednis-
one, and lenalidomide plus melphalan, prednisone, and lenalidomide; CRD: cyclophosphamide, lenalidomide, and dexamethasone;
CTD: cyclophosphamide, thalidomide, and dexamethasone; CTDa: cyclophosphamide, thalidomide, and dexamethasone (attenu-
ated); D: dexamethasone; Dþ IFN: dexamethasone and interferon alpha; Dþ Rd: daratumumab, lenalidomide, and dexamethasone;
KMP: carfilzomib, melphalan, and prednisone; MD: melphalan and dexamethasone; MP: melphalan and prednisone; MPR: melpha-
lan, prednisone, and lenalidomide; MPRþ R: melphalan, prednisone, and lenalidomide plus lenalidomide maintenance; MPT: mel-
phalan, prednisone, and thalidomide; MPTþ T: melphalan, prednisone, and thalidomide plus thalidomide maintenance; NR: not
reported; PFS: progression-free survival; OS: overall survival; Rd: lenalidomide and dexamethasone; Rd18: lenalidomide in 3 of 4-
week cycles; RVd: lenalidomide, bortezomib, and dexamethasone; TD: thalidomide and dexamethasone; VD: bortezomib and dexa-
methasone; VMP: bortezomib, melphalan, and prednisone; VMPþD: bortezomib, melphalan, prednisone, and daratumumab;
VMPþ S: bortezomib, melphalan, and prednisone plus siltuximab maintenance; VMPTþ VT: bortezomib, melphalan, prednisone,
and thalidomide plus thalidomide maintenance; VTP: bortezomib, thalidomide, and prednisone.
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RVd was the only regimen to demonstrate a signifi-
cant advantage over Rd in terms of OS, which is argu-
ably the most important efficacy endpoint when
evaluating novel therapies for NDMM [45]. The efficacy
and safety of RVd were demonstrated in the SWOG
S0777 trial, which compared RVd with Rd in patients
with NDMM who were not intended for ASCT [15]. A
recent update showed that at a median follow-up
period of 84months (7 years), the median OS for RVd
was not reached, and that there was a 12-month pro-
longation of median PFS with RVd over Rd [46]. In
addition to these findings, our NMA suggests that RVd
Table 2. Baseline age and ISS stage from RCTs in the primary analysis network.
Study Treatment N Age, median (range), y ISS stage 3, n (%) High-risk cytogenetic profilea, n (%)
VISTA [22] VMP 344 71 (57–90) 115 (34.0) 26 (7.5)
MP 338 71 (48–91) 119 (34.9) 20 (5.9)
IFM 01/01 [19,20] MPT 113 78.5 (75–89) 34 (30.1) NR
MP 116 78.5 (75–89) 31 (26.7) NR
IFM 99-06 [16] MPT 125 NR (65–75) 32 (25.6) NR
MP 196 NR (65–75) 54 (27.6) NR
MM03 [21] MPT 64 76 (66–89) 14 (21.9) NR
MP 54 79 (68–88) 16 (29.6) NR
FIRST [11,17,18,23] Rd 535 73 (44–91) 216 (40.4) 43 (8.0)
MPT 547 73 (51–92) 224 (41.0) 47 (8.6)
SWOG S0777 [15] Rd 261 63 (56–71)b 79 (34.5)c NR
RVd 264 63 (56–70)b 78 (32.2)c NR
ALCYONE [24] VMPþD 350 71 (40–93) 142 (40.6) 53 (15.1)
VMP 356 71 (50–91) 129 (36.2) 45 (12.6)
MAIA [25] Dþ Rd 368 73 (50–90) 107 (29.1) 48/319 (15.0)
Rd 369 74 (45–89) 110 (29.8) 44/323 (13.6)
Dþ Rd: daratumumab, lenalidomide, and dexamethasone; ISS: International Staging Score; MP: melphalan and prednisone; MPT: melphalan, prednisone,
and thalidomide; NR: not reported; RCT: randomized controlled trial; Rd: lenalidomide and dexamethasone; RVd: lenalidomide, bortezomib, and dexa-
methasone; VMP: bortezomib, melphalan, and prednisone; VMPþD: bortezomib, melphalan, prednisone and daratumumab.
aPresence of at least one of the following chromosomal aberrations: translocation (4;14), translocation (14;16), or deletion 17p.
bInterquartile range.
cCalculated on the population eligible for efficacy analysis.
Figure 3. Results of the primary analysis. (A) Overall survival (OS). (B) Progression-free survival (PFS). Data are HR (95% CrI). CrI:
credible interval; Dþ Rd: daratumumab, lenalidomide, and dexamethasone; HR: hazard ratio; MP: melphalan and prednisone; MPT:
melphalan, prednisone, and thalidomide; PFS: progression-free survival; OS: overall survival; Rd: lenalidomide and dexamethasone;
RVd: lenalidomide, bortezomib, and dexamethasone; VMP: bortezomib, melphalan, and prednisone; VMPþD: bortezomib, melpha-
lan, prednisone, and daratumumab.
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offers OS and PFS benefits over VMP and also the
older regimens, MP and MPT, which are no longer rec-
ommended by the NCCNVR based on the FIRST trial
data [2]. Other advantages of the RVd regimen include
the wide experience with the regimen in a real-world
clinical practice setting (in the USA), and the relatively
low cost compared with options like Dþ Rd [45].
Taken together, these observations and the findings
from our analysis provide further confidence in the
outcomes that are achievable with the RVd regimen.
Clinical and safety outcomes have recently been
published for Dþ Rd from the MAIA study, comparing
Dþ Rd with Rd [25]. As of July 2019, OS data from this
study are not available, however, the risk of disease
progression or death was 44% lower in the daratumu-
mab group compared to the Rd arm. PFS data are
also available for another relatively new regimen,
VMPþD, from phase-3 ALCYONE study [24]. Again, OS
data have yet to be reported so it is unclear whether
the reported 53% reduction in the risk of disease
Figure 4. Surface under the cumulative ranking plot for the primary analysis. (A) Overall survival (OS). (B) Progression-free survival
(PFS). Higher SUCRA scores indicate a higher probability that the treatment was in the top rank or one of the top ranks. Dþ Rd:
daratumumab, lenalidomide, and dexamethasone; ITT: intentionto-treat; MP: melphalan and prednisone; MPT: melphalan, prednis-
one, and thalidomide; PFS: progression-free survival; OS: overall survival; Rd: lenalidomide and dexamethasone; RVd: lenalidomide,
bortezomib, and dexamethasone; SUCRA: surface under the cumulative ranking curve; VMP: bortezomib, melphalan, and prednis-
one; VMPþD: bortezomib, melphalan, prednisone, and daratumumab.
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progression or death versus VMP will translate into a
survival benefit [47].
It is also relevant to compare the results for
VMPþD with SoC, in addition to VMP. Our study
aimed to address this by comparing VMPþD with Rd.
However, results of this comparison were inconclusive,
reflecting that Rd and VMPþD are separated by three
nodes in the network, resulting in broad CrIs.
Two other NMAs have addressed the relative effi-
cacy of treatment options for NDMM. An NMA com-
paring Rd with regimens investigated in RCTs that
included patients with NDMM who were aged
>65 years reported improved outcomes for response
rate, OS, and PFS for Rd, however RVd, VMP+D, and
Dþ Rd were not included in this analysis [48]. A
recently published NMA of treatments for patients
with TNE NDMM [49] used a random-effects model
with a wide evidence network similar to our extended
network. However, their conclusions differ slightly
from ours; the relative ordering of VMPþD and RVd
in terms of PFS impact is reversed, with VMPþD
ranked ahead of RVd. The authors do not report their
methodology, but the differences in findings may be
due to variations in the extracted HRs for dexametha-
sone from Kaplan–Meier curves in IFM-95/01 [37].
As in any indirect comparison, some limitations can
be expected in this analysis. However, intra- and inter-
trial inconsistencies and risk of bias were addressed.
Risk of bias in the primary network was generally low
in terms of blinding of outcome assessment (perform-
ance bias) and incomplete outcome data (detection
bias). NMAs are also limited by the assumption that
treatment effects are transitive [50].
In the primary analysis, the main intra-trial inconsist-
ency relates to the differences in age between treat-
ment groups in the SWOG S0777 trial; the Rd arm
contained a higher proportion of patients aged
65 years (48%) than the RVd arm (38%). However, sen-
sitivity analyses showed that the results were unaffected
by this imbalance, as reported by Durie et al. [46] in an
updated analysis. Furthermore, in the SWOG S0777 trial,
a small proportion of patients received unplanned
ASCT; inclusion of these patients could potentially influ-
ence the results of the analysis relating to RVd.
Inter-trial inconsistencies in the primary analysis
relate to differences in the median age and proportion
of patients with ISS stage 3. Differences in the propor-
tion of patients with renal impairment or high-risk
cytogenetics were also present, but these data were
not included in our analysis due to inconsistent
reporting between the published studies. In addition,
the VMP regimen used varied between trial: in the
ALCYONE trial patients received bortezomib twice
weekly in cycle 1 only, whereas in the VISTA trial
patients received bortezomib twice weekly during
cycles 1 to 4; this may have affected the results of
comparisons with VMPþD.
Similarly, differences in clinical management, moni-
toring, and patient follow-up likely exist between
studies. OS analyses are affected by treatments given
post-progression, which may differ between countries
and also vary based on when the study was con-
ducted, thereby increasing heterogeneity between
studies. Many of these differences are not reported in
sufficient detail by publications to allow adjustment or
consideration in sensitivity analyses.
Assumptions related to the analysis are also poten-
tial limitations of this study. The assumption that HRs
are constant—whereas they may be subject to change
based on follow-up duration (median follow-up in the
studies was 16–60months)—can lead to poor fit, as
seen in the fixed-effect models for the PFS extended
network. This could be overcome by modeling
Kaplan–Meier curves using fractional polynomial or
piecewise-constant models [51,52]. Consistency of
treatment effects across trials was assumed and,
because there were no independent loops of evi-
dence, could not be formally tested in the primary
analysis network. However, no evidence of inconsist-
ency was found in the extended network
(Supplementary Appendix 3). Our analysis also
assumed that no treatment-effect modifiers were
imbalanced across the network, but a network meta-
regression was not possible because only single trials
were available on majority of treatment contrasts [53].
This analysis supports the findings of the primary
studies identified in the SLR, indicating that first-line
treatment with Rd provides OS and PFS benefits over
the currently approved regimens available to TNE
patients with NDMM. Moreover, it establishes RVd as a
promising emerging therapeutic option that extends OS
and PFS compared with Rd for TNE patients with
NDMM; the recent positive opinion from European
Medicines Agency’s Committee for Medicinal Products
for Human Use on RVd supports our findings [54].
Evidence also suggests a role for both Dþ Rd and
VMPþD in the management of TNE NDMM, although
additional data are required to establish whether these
regimens extend OS as well as PFS versus current SoC.
As data from additional phase-3 studies of Rd and Vd
combinations become available, such as ixazomib plus
Rd, further updates to this NMA may help define the
role of new regimens in the treatment armamentarium
for MM. Finally, as patients aged 75 years constitute
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up to 40% of the NDMM population [55] and can be
both challenging to treat and under-represented in clin-
ical trials, studies focusing on this subgroup would help
define the optimal treatment regimens for
these patients.
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